Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease

Citation
Lp. De Almeida et al., Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease, NEUROBIOL D, 8(3), 2001, pp. 433-446
Citations number
81
Categorie Soggetti
Neurosciences & Behavoir
Journal title
NEUROBIOLOGY OF DISEASE
ISSN journal
09699961 → ACNP
Volume
8
Issue
3
Year of publication
2001
Pages
433 - 446
Database
ISI
SICI code
0969-9961(200106)8:3<433:NEOACL>2.0.ZU;2-B
Abstract
Neurodegenerative diseases represent promising targets for gene therapy app roaches provided effective transfer vectors. In the present study, we evalu ated the effectiveness of LacZ-expressing lentiviral vectors with two diffe rent internal promoters, the mouse phosphoglycerate kinase 1 (PGK) and cyto megalovirus (CMV), to infect striatal cells. The intrastriatal injection of lenti-beta -Gal vectors lead to 207, 400 +/- 11,500 and 303,100 +/- 4,300 infected cells in adult rats, respectively. Importantly, the beta -galactos idase activity was higher in striatal extracts from PGK-LacZ-injected anima ls as compared to CMV-LacZ animals. The efficacy of the system was further examined with a potential therapeutic gene for the treatment of Huntington' s disease, the human ciliary neurotrophic factor (CNTF). PGK-LacZ- or PGK-C NTF-expressing viruses were stereotaxically injected into the striatum of r ats, 3 weeks later the animals were unilaterally lesioned with 180 nmol of quinolinic acid (QA). Control animals displayed 148 +/- 43 apomorphine-indu ced rotations ipsilateral to the lesion 5 days postlesion as compared to 26 +/- 22 turns/45 min in the CNTF-treated group. The extent of the striatal damage was significantly diminished in the CNTF-treated rats as indicated b y the 52 +/- 9.7% decrease of the lesion volume and the sparing of DARPP-32 , ChAT and NADPH-d neuronal populations. These results further establish th at lentiviruses may represent an efficient gene delivery system for the scr eening of therapeutic molecules in Huntington's disease. (C) 2001 Academic Press.